We are a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases, addressing unmet medical needs.
We were delighted to welcome
@ScotGovFM
@NicolaSturgeon
to our Livingston vaccine manufacturing site today, where she met staff who are playing a critical role in the manufacture of our inactivated
#COVID19
vaccine candidate
โผ๏ธ EMA starts
#RollingReview
of Valnevaโs
#COVID19vaccine
.
Studies in adults show that this inactivated vaccine triggers the production of antibodies that target the
#coronavirus
.
๐
Independent vaccine expert Otfried Kistner discussed Valneva's
#inactivated
#COVID19
#vaccine
candidate on
@PULS24news
, calling it a potential "great alternative" for those who want a vaccine based on a proven technology. Click here to watch (in German):
โFill and finishโ is the final step of
#vaccine
#manufacturing
, when doses are bottled and made ready for delivery. At Valneva, this takes place at our Solna, Sweden location. Watch the video below for an inside look:
First doses of Valneva's inactivated
#COVID19
#vaccine
were shipped from our site in Sweden & have arrived in Bahrain.
Bahrainโs Health Minister, CEO of the NHRA & other officials joined the French Ambassador & Valneva executives for this important event
As 2021 comes to a close, weโd like to thank the entire Valneva team for their continued effort, hard work and dedication throughout the past twelve months. We look forward to whatโs in store for us in 2022 and beyond!
#DYK
that in 2021
#COVID19
vaccine outputs were estimated at over 12 billion doses & are expected to hit 24 billion by mid-2022, according to the
@IFPMA
? ()
Take an inside look at our GMP manufacturing facilities in Scotland:
We are grateful to everyone who has contributed to the clinical trials of our inactivated
#COVID19
vaccine - from partners to investigators and participants. Yesterday's Conditional Marketing Authorization from
@MHRAgovuk
highlights the value of collaboration.
#VaccinesWork
Regulators at
@MHRAgovuk
have today approved the use of the Valneva vaccine in the UK.ย
We would like to recognise and thank all the research staff and the 4,000 participants across the UK involved in the study, for their efforts, patience and altruism.
Today weโve met a big milestone, with the first volunteer being vaccinated in the Phase 3 trial of our inactivated
#COVID19
vaccine candidate - especially exciting to be taking place during
#WorldImmunizationWeek
! To find out more about taking part visit:
#ICYMI
We successfully completed the pivotal Phase 3 trial of our single-shot chikungunya vaccine candidate, VLA1553, early last month. Check out this
@biospace
article for more:
Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001
#TropMed21
- Today, Valnevaโs Chief Medical Officer, Juan Carlos Jaramillo, MD presented โChikungunya: Phase 3 Clinical Development of a Single-shot Live-attenuated Vaccineโ at the
@ASTMH
2021 Annual Meeting
Das Stellungnahmeverfahren zur neuen Impfempfehlung der Stรคndigen Impfkommission (
#STIKO
) wurde eingeleitet: Personen ab 18 Jahren wird kรผnftig alternativ zu den bereits empfohlenen COVID-19-Impfstoffen der
#Totimpfstoff
#Valneva
zur Grundimmunisierung empfohlen.
We are thrilled to inaugurate our new facility in
#Sweden
today with Social Affairs Minister
@lenahallengren
. The state-of-the-art Hans Wigzell Vaccine Facility will allow us to fill & distribute millions of doses per year and is an expansion of our longstanding presence in Solna
Valneva is an established vaccine company. Our primary focus is the development & commercialization of prophylactic vaccines for
#InfectiousDiseases
with significant unmet medical need. Learn more about us here:
#AdvancingVaccinesForBetterLives
Dr. Christoph Jandl (second from the left), Head of Medical Affairs, Valneva Austria, presenting our inactivated whole-virus
#COVID19
vaccine technology at todayโs
@OEVIH_AT
Press Briefing. The briefing was focused on broadening the COVID-19 vaccine and prophylactic portfolio.
Valneva Sweden Managing Director Janet Hoogstraate recently spoke about the first commercial shipment of Valnevaโs inactivated
#COVID19
vaccine to leave the Solna facility for Bahrain. โThis is a major milestone for us at Valnevaโฆโ she said.
At Valneva, we develop, produce and commercialize prophylactic vaccines for infectious diseases with significant unmet medical need. Learn more about several of our vaccines in development here:
We're creating a new high-level vaccine manufacturing facility in Livingston, Scotland, to boost production capacity for our inactivated
#COVID19
vaccine. Today, our CEO Thomas Lingelbach was pleased to join the project leadership team for its first on site meeting.
@BouyguesESUK
#DYK
that there are no preventative vaccines or treatments available for the chikungunya virus, a viral disease transmitted to humans by infected mosquitoes? At Valneva, weโre dedicated to developing a vaccine for this major unmet need. Learn more here:
.
@ScotGovFM
@NicolaSturgeon
and Business Minister
@Ivan_McKee
visited Valneva's new state-of-the-art large-scale manufacturing plant, which is being operationalized with support from
@scotent
to boost existing vaccine production capacity & create critical national infrastructure
Today, the Valneva team were honored to ring the opening bell for
@Nasdaq
. We would like to thank all our employees, our partners and our shareholders for their continued dedication and support and we look forward to a great year in 2023!
Valnevaโs success stems from the dedication and expertise of over 750 employees spanning the whole value chain, from R&D to commercialization. Learn more in our 2021 Annual Business Report:
Today is
#ClinicalTrialAwarenessDay
and we want to thank the healthcare professionals, medical researchers and volunteers who strive to make a difference and contribute to the development of new solutions for patients around the world.
#Research
#ClinicalTrials
#ThankYou
Following the delivery of the first doses of our
#inactivated
whole-virus
#COVID19
vaccine candidate to Bahrain, Valneva CMO
@JCJaramillo_CMO
appeared live on Bahrain International TV's "Inside Edition" program:
โถ Conseil europรฉen :
#EmmanuelMacron
s'exprime.
๐ฃ
#Vaccination
: "L'UE se met en capacitรฉ de produire de maniรจre beaucoup plus autonome et durable car il est vraisemblable que nous aurons ร vivre avec ce virus dans la durรฉe".
๐บ
#Le20HdeLCI
avec
@EliMartichoux
.
#WorldImmunizationWeek
starts today. From the beginning, Valnevaโs vision has always been to contribute to a world where no one dies or suffers from a vaccine-preventable disease. Weโre proud to support this campaign again in 2022
#LongLifeForAll
@WHO
On Wednesday, Valneva was pleased to host Chris Barton CMG, Her Majestyโs Trade Commissioner for Europe; Emma Baines, Deputy Head of Mission; Bronwen Moore, Country Director DIT Austria; and Markus Hauser, DIT/Head of Inward Investment at our site in Vienna, Austria
#ICYMI
@Gulf_News
, the leading English-language paper in the United Arab Emirates, covered Bahrainโs recent approval of our
#COVID19
vaccine. Read more here:
#vaccines
Today, we announced the pricing of our
#IPO
and began trading on
@Nasdaq
under the ticker symbol $VALN. We are so excited for this next chapter as a company and cannot thank our team enough for their commitment to the Valneva mission!
#ValnevaNasdaqIPO
๐๐
The
#Chikungunya
virus is transmitted to people by mosquito bites. It can be imported to new areas by infected travelers. There are no preventive vaccines so people traveling to endemic countries should take precautionary measures. Learn more from
@CDCgov
: